Physician profile
Daniel Hampton
NPI 1154597979
$1,538.22
in general payments reported to CMS, 2019-2025
21 companies · $242 in 2025
The $242 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $491 · 2020: $43.16 · 2021: $43.93 · 2022: $240 · 2023: $288 · 2024: $189 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $704 · Education: $16.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $703.71 |
| Education | $16.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $355.18 | 2019-2025 | |
| Abbvie INC. | $225.85 | 2019-2025 | |
| Pfizer INC. | $199.51 | 2019-2022 | |
| Janssen Biotech, INC. | $146.96 | 2019-2023 | Simponi Aria, Simponi, Stelara |
| Celgene Corporation | $106.48 | 2022-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $93.09 | 2019-2025 | Gattex, Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.79 | 2023-2025 | Xifaxan |
| Ethicon US, LLC | $45.57 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $39.25 | 2021-2022 | |
| Lilly USA, LLC | $37.05 | 2024 | Omvoh |
| Ardelyx, INC. | $26.35 | 2023 | Ibsrela |
| Genzyme Corporation | $21.35 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $20.94 | 2022 | |
| Madrigal Pharmaceuticals | $19.13 | 2024 | Resmetirom |
| Organon LLC | $18.46 | 2025 | Hadlima, Renflexis |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $18.38 | 2022 | |
| Novo Nordisk INC | $16.64 | 2023 | Wegovy |
| Celltrion USA INC. | $16.17 | 2024 | Zymfentra |
| Aimmune Therapeutics, INC. | $14.29 | 2024 | |
| Intercept Pharmaceuticals, INC. | $14.05 | 2023 | Ocaliva |
| Alexion Pharmaceuticals, INC. | $13.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hampton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.